New Stroke Trial Highlights Limitations of Artery Reopening in Patient Recovery
A recent stroke trial conducted across 14 hospitals in Spain has revealed that reopening a blocked artery through thrombectomy is not always sufficient for patient recovery. The study, led by Dr. Arturo Renú, focused on the use of alteplase, a clot-dissolving drug, administered directly into the brain artery after thrombectomy. The trial involved 440 adults and aimed to address the issue of microcirculation blockages in small vessels that remain after the main artery is cleared. Results showed that patients receiving alteplase had a 57.5% rate of excellent functional outcomes compared to 42.5% in the thrombectomy-only group. However, the alteplase group also experienced a higher mortality rate of 12.1% compared to 6.4% in the thrombectomy-only group, indicating a need for further study on the safety of this approach. 
